ERBB2 and breast carcinoma: DS-8201a has a high drug-antibody ratio, high cell membrane permeability, and potent bystander effect, DS-8201a has been approved for the second-line and above treatment of metastatic HER2-positive breast cancer and HER-2 low-expressing breast cancer (IHC 1+ or 2+/ISH-).